Compare Stocks: LFWD, RNXT, CVRX, and HSAQ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVRX CVRx	$2.72 -5.9%	$3.64	$2.20 ▼ $11.30	$76.99M	0.76	571,368 shs	481,615 shs
HSAQ Health Sciences Acquisitions Co. 2	$6.22 -0.5%	$4.80	$9.41 ▼ $13.80	$69.74M	0.09	205,918 shs	343,049 shs
LFWD Lifeward	$7.08 +1.9%	$7.30	$4.14 ▼ $10.56	$19.65M	0.39	4,257 shs	6,415 shs
RNXT RenovoRx	$1.63 -4.1%	$1.41	$0.70 ▼ $2.59	$76.72M	1.12	1.47 million shs	765,004 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVRX CVRx	-5.88%	-9.93%	-13.65%	-48.19%	-63.49%
HSAQ Health Sciences Acquisitions Co. 2	-0.48%	+2.98%	+16.04%	+56.28%	+154.92%
LFWD Lifeward	+0.01%	+2.39%	-2.95%	+2.83%	-13.74%
RNXT RenovoRx	-4.12%	+5.16%	+30.40%	+75.27%	+32.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVRX CVRx	$2.72 -5.9%	$3.64	$2.20 ▼ $11.30	$76.99M	0.76	571,368 shs	481,615 shs
HSAQ Health Sciences Acquisitions Co. 2	$6.22 -0.5%	$4.80	$9.41 ▼ $13.80	$69.74M	0.09	205,918 shs	343,049 shs
LFWD Lifeward	$7.08 +1.9%	$7.30	$4.14 ▼ $10.56	$19.65M	0.39	4,257 shs	6,415 shs
RNXT RenovoRx	$1.63 -4.1%	$1.41	$0.70 ▼ $2.59	$76.72M	1.12	1.47 million shs	765,004 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVRX CVRx	-5.88%	-9.93%	-13.65%	-48.19%	-63.49%
HSAQ Health Sciences Acquisitions Co. 2	-0.48%	+2.98%	+16.04%	+56.28%	+154.92%
LFWD Lifeward	+0.01%	+2.39%	-2.95%	+2.83%	-13.74%
RNXT RenovoRx	-4.12%	+5.16%	+30.40%	+75.27%	+32.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVRX CVRx	2.17	Hold	$4.30	58.09% Upside
HSAQ Health Sciences Acquisitions Co. 2	0.00	N/A	N/A	N/A
LFWD Lifeward	2.25	Hold	$10.00	41.34% Upside
RNXT RenovoRx	2.75	Moderate Buy	$8.50	421.47% Upside

Current Analyst Ratings Breakdown

Latest LFWD, RNXT, CVRX, and HSAQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	CVRX CVRx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
9/2/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	LFWD Lifeward	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	LFWD Lifeward	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/18/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CVRX CVRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$13.00 ➝ $5.00
8/7/2026	CVRX CVRx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$4.00
8/7/2026	CVRX CVRx	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$4.00
8/7/2026	CVRX CVRx	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$14.00 ➝ $3.50

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVRX CVRx	$56.65M	1.28	N/A	N/A	$1.50 per share	1.81
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	($0.62) per share	N/A
LFWD Lifeward	$22.03M	0.91	N/A	N/A	$5.52 per share	1.28
RNXT RenovoRx	$1.12M	65.68	N/A	N/A	$0.15 per share	10.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVRX CVRx	-$53.31M	-$1.98	N/A	N/A	N/A	-84.93%	-152.35%	-50.93%	11/4/2026 (Estimated)
HSAQ Health Sciences Acquisitions Co. 2	-$380K	N/A	N/A	N/A	N/A	N/A	N/A	-2.38%	N/A
LFWD Lifeward	-$19.91M	-$16.82	N/A	N/A	N/A	-141.28%	-235.86%	-81.72%	11/13/2026 (Estimated)
RNXT RenovoRx	-$11.17M	-$0.31	N/A	N/A	N/A	-621.71%	-135.11%	-101.91%	11/12/2026 (Estimated)

Latest LFWD, RNXT, CVRX, and HSAQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2026	Q2 2026	LFWD Lifeward	-$1.39	-$1.46	-$0.07	-$4.12	$6.53 million	$6.62 million
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.0725	-$0.05	+$0.0225	-$0.06	$0.70 million	$0.91 million
8/6/2026	Q2 2026	CVRX CVRx	-$0.5246	-$0.53	-$0.0054	-$0.53	$15.55 million	$15.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVRX CVRx	N/A	N/A	N/A	N/A	N/A
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVRX CVRx	2.94	8.04	6.87
HSAQ Health Sciences Acquisitions Co. 2	N/A	0.17	0.61
LFWD Lifeward	0.70	2.33	1.77
RNXT RenovoRx	N/A	5.74	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVRX CVRx	75.27%
HSAQ Health Sciences Acquisitions Co. 2	89.71%
LFWD Lifeward	26.76%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
CVRX CVRx	16.60%
HSAQ Health Sciences Acquisitions Co. 2	21.90%
LFWD Lifeward	1.50%
RNXT RenovoRx	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVRX CVRx	223	26.64 million	22.22 million	Optionable
HSAQ Health Sciences Acquisitions Co. 2	4	11.21 million	8.76 million	Not Optionable
LFWD Lifeward	81	2.83 million	2.79 million	Optionable
RNXT RenovoRx	17	45.13 million	40.89 million	Not Optionable

LFWD, RNXT, CVRX, and HSAQ Headlines

Recent News About These Companies

RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Update

September 17, 2026 | marketbeat.com

RenovoRx HC Wainwright presentation to highlight RenovoCath growth and Phase III TIGeR-PaC timeline

September 2, 2026 | msn.com

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

September 2, 2026 | globenewswire.com

FY2026 EPS Estimate for RenovoRx Increased by Analyst

September 2, 2026 | marketbeat.com

RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 137.8% in August

August 28, 2026 | marketbeat.com

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced ...

August 25, 2026 | finance.yahoo.com

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

August 25, 2026 | globenewswire.com

RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update

August 21, 2026 | kalkinemedia.comK

RenovoRx regains Nasdaq compliance

August 21, 2026 | msn.com

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 21, 2026 | globenewswire.com

RenovoRx Regains Nasdaq Compliance on Minimum Bid Price

August 20, 2026 | tipranks.com

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

August 20, 2026 | globenewswire.com

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Q2 FY2026 earnings call transcript

August 12, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2026 | zacks.com

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

August 12, 2026 | markets.businessinsider.com

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

August 11, 2026 | markets.businessinsider.com

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

August 6, 2026 | globenewswire.com

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

August 4, 2026 | globenewswire.com

RenovoRx (RNXT) Stock Forecast & Price Target

August 2, 2026 | investing.com

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

July 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, RNXT, CVRX, and HSAQ Company Descriptions

CVRx NASDAQ:CVRX

$2.72 -0.17 (-5.88%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.73 +0.01 (+0.37%)

As of 04:57 AM Eastern

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$6.22 -0.03 (-0.48%)

As of 09/22/2026

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Lifeward NASDAQ:LFWD

$7.08 +0.14 (+1.95%)

Closing price 09/23/2026 03:58 PM Eastern

Extended Trading

$7.08 0.00 (0.00%)

As of 09/23/2026 07:30 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

RenovoRx NASDAQ:RNXT

$1.63 -0.07 (-4.12%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.56 -0.06 (-3.99%)

As of 07:21 AM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LFWD, RNXT, CVRX, and HSAQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LFWD, RNXT, CVRX, and HSAQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LFWD, RNXT, CVRX, and HSAQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, RNXT, CVRX, and HSAQ Company Descriptions

CVRx NASDAQ:CVRX

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

Lifeward NASDAQ:LFWD

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LFWD, RNXT, CVRX, and HSAQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LFWD, RNXT, CVRX, and HSAQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LFWD, RNXT, CVRX, and HSAQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, RNXT, CVRX, and HSAQ Company Descriptions

CVRx NASDAQ:CVRX

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

Lifeward NASDAQ:LFWD

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools